Mucormycosis during COVID-19 era: A retrospective assessment

• Published in: Infectious medicine 2024-06, Vol.3 (2), p.100112, Article 100112
• Main Authors: Mukherjee, Tuhin, Das, Tanisha, Basak, Sourav, Mohanty, Satyajit, Adhikary, Krishnendu, Chatterjee, Prity, Maiti, Rajkumar, Karak, Prithviraj
• Format: Article
• Language: English
• Subjects: COVID-19; Fungal agents; Mucormycosis; Pandemic
• ISSN: 2772-431X; 2772-431X
• DOI: 10.1016/j.imj.2024.100112

•Immunological and pathological correlations of Mucormycosis.•Involvement of iron in the pathogenesis of Mucormycosis.•The elevated risk factors caused due to Mucormycosis.•Complications in Assessing Treatment Strategies in Mucormycosis.•Antifungal Agents in the Treatment and Management of Mucormycosis. In a retrospective view, this review examines the impact of mucormycosis on health workers and researchers during the COVID era. The diagnostic and treatment challenges arising from unestablished underlying pathology and limited case studies add strain to healthcare systems. Mucormycosis, caused by environmental molds, poses a significant threat to COVID-19 patients, particularly those with comorbidities and compromised immune systems. Due to a variety of infectious Mucorales causes and regionally related risk factors, the disease's incidence is rising globally. Data on mucormycosis remains scarce in many countries, highlighting the urgent need for more extensive research on its epidemiology and prevalence. This review explores the associations between COVID-19 disease and mucormycosis pathology, shedding light on potential future diagnostic techniques based on the fungal agent's biochemical components. Medications used in ICUs and for life support in ventilated patients have been reported, revealing the challenge of managing this dual onslaught. To develop more effective treatment strategies, it is crucial to identify novel pharmacological targets through “pragmatic” multicenter trials and registries. In the absence of positive mycology culture data, early clinical detection, prompt treatment, and tissue biopsy are essential to confirm the specific morphologic features of the fungal agent. This review delves into the history, pathogens, and pathogenesis of mucormycosis, its opportunistic nature in COVID or immunocompromised individuals, and the latest advancements in therapeutics. Additionally, it offers a forward-looking perspective on potential pharmacological targets for future drug development. Graphical representation of mucormycosis infection and therapeutic interventions [Display omitted]